SEARCH

SEARCH BY CITATION

References

  • Anastasio NC, Johnson KM (2007). Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. J Neurochem; November 8 [e-pub ahead of print].
  • Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P et al. (1992). Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49: 943958.
  • Arguello PA, Gogos JA (2006). Modeling madness in mice: one piece at a time. Neuron 52: 179196.
  • Barbon A, Fumagalli F, La Vie L, Caracciolo L, Racagni G, Andrea Riva M et al. (2007). Chronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortex. Exp Neurol 208: 5462.
  • Beasley CL, Zhang ZJ, Patten I, Reynolds GP (2002). Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 52: 708715.
  • Berman KF, Doran AR, Picker D, Weinberger DR (1993). Is the mechanism of prefrontal cortex hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry 162: 183192.
  • Buchsbaum MS, Nuechterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E et al. (1990). Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br J Psychiatry 156: 216227.
  • Cho RY, Konecky RO, Carter CS (2006). Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci USA 103: 1987819883.
  • Cochran SM, Fujimura M, Morris BJ, Pratt JA (2002). Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse 46: 206214.
  • Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003a). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28: 265275.
  • Cochran SM, Morris BJ, Pratt JA (2003b). Chronic PCP-induced changes in the levels of mRNA encoding the Kv3 subfamily of voltage gated potassium channels in the rat brain. Soc Neurosci 754: 12.
  • Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 6575.
  • Egerton A, Reid L, McGregor S, Cochran SM, Morris BJ, Pratt JA (2008). Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology; DOI:DOI: 10.1007/s00213-008-1071-5.
  • Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005). Impairment in perceptual attentional set shifting following PCP administration: a rodent model of cognitive dysfunction in schizophrenia. Psychopharmacology 179: 7784.
  • Enomoto T, Noda Y, Nabeshima T (2007). Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 29: 294301.
  • Gao XM, Shirakawa O, Du F, Tamminga CA (1993). Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 241: 715.
  • Green MF (2006). Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67 (Suppl 9): 38; discussion 36-42. Review.
  • Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 4068.
  • Harvey PO, Fossati P, Pochon JB, Levy R, Lebastard G, Lehericy S et al. (2005). Cognitive control and brain resources in major depression: an fMRI study using the n-back task. Neuroimage 26: 860869.
  • Hazlett EA, Buchsbaum MS, Jeu LA, Nenadic I, Fleischman MB, Shihabuddin L et al. (2000). Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr Res 43: 3346.
  • Homayoun H, Moghaddam B (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurones and pyramidal neurones. J Neurosci 27: 1149611500.
  • Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 13011308.
  • Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201225.
  • Joyce E, Hutton S, Mutsatsa S, Gibbins H, Webb E, Paul S et al. (2002). Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry Suppl 43: s38s44.
  • Kawaguchi Y, Kondo S (2002). Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. J Neurocytol 31: 277287.
  • Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al., CATIE Investigators; Neurocognitive Working Group (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633647.
  • Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199214.
  • Large CH (2007). Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs J Psychopharmacol 21: 283301.
  • Lewis DA (2000). GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 31: 270276.
  • Lewis DA, Hashimoto T, Vok DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312314.
  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 12091223.
  • Lipska BK (2004). Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatric Neurosci 29: 282286.
  • Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al. (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301307.
  • Morris BJ, Cochran SM, Pratt JA (2005). PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5: 101106.
  • Newell KA, Zavitsanou K, Huang XF (2007). Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J Neural Transm 114: 9951001.
  • Olney JW, Labrugere J, Price MT (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 13601362.
  • Ragland JD, Yoon J, Minzenberg MJ, Carter CS (2007). Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism. Int Rev Psychiatry 19: 417427.
  • Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K et al. (2004). Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 50: 111.
  • Rudy B, McBain CJ (2001). Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends Neurosci 24: 517526.
  • Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H et al. (2006). A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioural abnormalities. Biol Psychiatry 59: 721729.
  • Snitz BE, MacDonald A, Cohen JD, Cho RY, Becker T, Carter CS (2005). Lateral and medial hypofrontality in first episode schizophrenia: functional activity in a medication-naïve state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry 162: 23222329.
  • Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN et al. (1992). Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49: 522530.
  • Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, Mentzel H et al. (1999). Decreased frontal activation in schizophrenics during stimulation with the continuous performance test: a functional magnetic resonance imaging study. Eur Psychiat 14: 1724.
  • Wang CZ, Johnson KM (2005). Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 81: 284292.
  • Wang CZ, Yang SF, Johnson KM (2007). Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurones. Neuropsychopharmacology; December 5 [e-pub ahead of print] PMID: 18059437.
  • Weissman AD, Dam M, London ED (1987). Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 435: 2940.
  • Winchester CL, O'Donovan LH, Pratt JA, Morris BJ (2007). Schizophrenia: from gene arrays to novel drug targets. Schizophr Bull 33: p305.
  • Zhao J, He X, Liu Z, Yang D (2006b). The effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile of schizophrenia. Int J Psychiatry Med 36: 171181.
  • Zhao X, Li H, Shi Y, Tang R, Chen W, Liu J et al. (2006a). Significant association between the genetic variations in the 5′ end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 59: 747753.
  • Zhu Y, Stornetta RL, Zhu JJ (2004). Chandelier cells control excessive cortical excitation: characteristics of whisker-evoked synaptic responses of layer 2/3 nonpyramidal and pyramidal neurons. J Neurosci 24: 51015108.